Álvaro F. V. G.
- Country
- Spain
- Department
- OFTALMOLOGIA
Research Overview
- Phase 3 Evaluation of Ripasudil (K-321) Eye Drops on Visual Acuity Post-Descemetorhexis in Fuchs Endothelial Corneal Dystrophy Patients
- Evaluation of Intravitreal OPT-302 and Aflibercept Versus Aflibercept Monotherapy in Neovascular Age-related Macular Degeneration Patients
- A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12 Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy
Data & Insights
Has run more than one trial at 14 of 80 partner sites.
Specializations
Macular Degeneration Research
The investigator specializes in treating neovascular age-related macular degeneration (nAMD), with particular focus on innovative delivery systems and combination therapies.
- Port Delivery System Technology
- Long-term Treatment Efficacy
- Novel Therapeutic Combinations
Research interests include extended-duration treatment regimens and advanced drug delivery mechanisms for retinal conditions.
Corneal Disorders
The investigator conducts research in Fuchs Endothelial Corneal Dystrophy (FECD), exploring innovative therapeutic approaches for this degenerative eye condition.
- Corneal Endothelial Treatment
- Visual Acuity Improvement
- Post-surgical Interventions
Areas of focus include therapeutic interventions following descemetorhexis and combined approaches with cataract surgery.
Ophthalmic Therapeutics
The investigator evaluates novel pharmacological interventions for various eye conditions, with emphasis on drug safety and efficacy profiles.
- Extended Release Formulations
- Treatment Optimization
- Visual Function Assessment
Research encompasses both established and experimental therapeutic approaches in ophthalmology.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.